Editas Medicine Names James C. Mullen as Chairman of the Board of Directors – Markets Insider
Nasdaq Fortune |
Editas Medicine Names James C. Mullen as Chairman of the Board of Directors
Markets Insider As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the … Comparing Editas Medicine (EDIT) and NewLink Genetics (NLNK) Head-To-Head Review: OpGen (OPGN) & Editas Medicine (EDIT) Financial Newsletter – Zacks |
